Silodosin, a novel selective α1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia

Expert Opinion on Investigational Drugs

Volumn 16, Issue 12, 2007, Pages 1955-1965

  Yoshida, Masaki ^a   Homma, Yukio ^a   Kawabe, Kazuki ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

1A adrenoceptor selective antagonist; Benign prostatic hyperplasia; Lower urinary tract symptoms; Silodosin; Tamsulosin

Indexed keywords

2 [[2 (2,6 DIMETHOXYPHENOXY)ETHYL]AMINOMETHYL] 1,4 BENZODIOXAN; 8 [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] 8 AZASPIRO[4.5]DECANE 7,9 DIONE; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; NAFTOPIDIL; NORADRENALIN; PHENYLEPHRINE; PLACEBO; PRAZOSIN; QUINAZOLINE DERIVATIVE; SILODOSIN; TAMSULOSIN; ADRENERGIC RECEPTOR ALPHA(1A); ALPHA 1 ADRENERGIC RECEPTOR; INDOLE DERIVATIVE; UNCLASSIFIED DRUG;

ABNORMAL LABORATORY RESULT; AREA UNDER THE CURVE; BLADDER NECK STENOSIS; CLINICAL TRIAL; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE KIDNEY FUNCTION RELATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION DISORDER; ELDERLY CARE; FOOD DRUG INTERACTION; GLUCOSURIA; HEART RATE; HUMAN; HYPOGASTRIC NERVE; HYPOTENSION; IRIS DISEASE; KIDNEY DYSFUNCTION; LONG TERM CARE; LOOSE FECES; LOW DRUG DOSE; LOWER URINARY TRACT SYMPTOM; MAXIMUM PLASMA CONCENTRATION; MEAN ARTERIAL PRESSURE; MICTURITION DISORDER; MORNING DOSAGE; NERVE STIMULATION; NONHUMAN; NOSE CONGESTION; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; THIRST; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSURETHRAL RESECTION; UPPER RESPIRATORY TRACT INFECTION; URETHRA PRESSURE; URINE INCONTINENCE; URINE SEDIMENT; VITAL SIGN; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; MALE; METHODOLOGY; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; INDOLES; MALE; PROSTATIC HYPERPLASIA; RECEPTORS, ADRENERGIC, ALPHA-1;

EID: 39549086056     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.12.1955     Document Type: Review

References (41)

1. ANDERSSON KE, GRATZKE C: Pharmacology of α1-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat. Clin. Pract. Urol. (2007) 4:368-378.
2. AUA PRACTICE GUIDELINES COMMITTEE: AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1. Diagnosis and treatment recommendations. J. Urol. (2003) 170:530-547.
3. 1-adrenoceptor subtypes in human hypertrophied prostate by in situ hybridization. Histochem. J. (1996) 28:283-288.
4. 1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and nonhypertrophied tissue. Br. J. Pharmacol. (1996) 119:797-803.
5. 2- and β-adrenoceptors in the urinary bladder, urethra and prostate. Br. J. Pharmacol. (2006) 147:S88-S119.
6. 1-Adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J. Urol. (2004) 171:1029-1035.
7. 1-Adrenoceptor selectivity and the treatment of benign prostatic hyperplasia and lower urinary tract symptoms. Prostate Cancer Prostatic. Dis. (2000) 3:76-83.
8. 1-adrenoceptors and native tissues. Mol. Pharmacol. (1955) 48:250-258.
9. YAMAZAKI Y: Development of silodosin. Yakugaku Zasshi (2006) 126:207-208.
10. ZHU J, TANIGUCHI T, TAKAUJI R, SUZUKI F, TANAKA T, MURAMATSU I: Inverse agonism and neutral antagonism at a constitutively active α-1a adrenoceptor. Br. J. Pharmacol. (2000) 131:546-552.
11. 1-adrenoceptor antagonists. Yakugaku Zasshi (2006) 126:187-198.
12. ZHANG L, TANIGUCHI T, TANAKA T et al.: α-1 Adrenoceptor up-regulation induced by prazosin but not KMD-3213 or reserpine in rats. Br. J. Pharmacol. (2002) 135:1757-1764.
13. 1-Adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213). Yakugaku Zasshi (2006) 126:209-216.
14. 1-adrenoceptor-selective antagonist, on the contractions of rabbit prostate and rabbit and rat aorta. Eur. J. Pharmacol. (1996) 315:73-79.
15. 1-adrenoceptors in vascular smooth muscle. Br. J. Pharmacol. (1990) 99:197-201.
16. 1-adrerioceptor antagonist, in human prostate and vasculature. J. Urol. (2000) 164:578-583.
17. MORISHIMA S, TANAKA T, YAMAMOTO H et al.: Identification of α-1L and α-1A adrenoceptors in human prostate by tissue segment binding. J. Urol. (2007) 177:377-381.
18. PRICE DT, SCHWINN DA, LOMASNEY JW, ALLEN LF, CARON MG, LEFKOWITZ RJ: Identification, quantification, and localization of mRNA for three distinct α 1 adrenergic receptor subtypes in human prostate. J. Urol. (1993) 150:546-551.
19. 1-adrenoceptor subtype mRNAs in human proximal urethra. Br. J. Pharmacol. (1998) 123:1289-1293.
20. 1a-adrenoceptor subtype in the rat, monkey and human urinary bladder and prostate. J. Urol. (1997) 157:1032-1038.
21. TATEMICHI S, KOBAYASHI K, MARUYAMA I et al.: Effects of silodosin (KMD-3213) on phenylephrine-induced increase in intraurethral pressure and blood pressure in rats - study of the selectivity for lower urinary tract. Yakugaku Zasshi (2006) 126:217-223.
22. 1a-adrenoceptor antagonist, tested in a novel rat model. J. Pharmacol. Exp. Ther. (1999) 291:81-91.
23. TOMIYA Y, TAKEMACHI S, TADACHI M et al.: Effect of silodosin on intraurethral pressure increase induced by hypogastric nerve stimulation in dogs with benign prostatic hyperplasia. Yakugaku Zasshi (2006) 126:225-230.
24. SHIMIZU T, MIYASHITAI I, MATSUBARA Y et al.: Pharmacokinetic profile of silodosin in clinical practice. Yakugaku Zasshi (2006) 126:257-263.
25. 1A-adrenoceptorselective antagonist for treating benign prostatic hyperplasia: results of a Phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int. (2006) 98:1019-1024.
26. 1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia: Phase III long-term study. Jpn Urol. Surg. (2006) 19:153-164.
27. 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br. J. Pharmacol. (1994) 113:723-728.
28. 1-adrenoceptor. Br. J. Pharmacol. (1996) 119:1093-1100.
29. 1 antagonist REC 15/2739 (SB 216469): role of the α1L adrenoceptors in tissue selectivity, part II. J. Pharmacol. Exp. Ther. (1997) 281:1284-1293.
30. 1-adrenoceptor antagonist with uroselective properties. J. Pharmacol. Exp. Ther. (2002) 300:478-486.
31. 1A adrenoceptor antagonist for the symptomatic treatment of benign prostatic hyperplasia. J. Med. Chem. (1997) 40:3141-3143.
32. 1D adrenoceptors. Naunyn Schmiedeberg's Arch. Pharmacol. (2001) 363:649-662.
33. 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). Br. J. Urol. (1997) 80:587-596.
34. SCHULMAN CC: Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment. Urology (2003) 62(Suppl. 3A):24-33.
35. 1-adrenoceptor subtype mRNAs in human vas deferens: comparison with those of epididymal and pelvic portions. Br. J. Pharmacol. (1997) 122:1009-1014.
36. SCHOU J, HOLM NR, MEYHOFF HH: Sexual function in patients with symptomatic benign prostatic hyperplasia. Scand. J. Urol. Nephrol. Suppl. (1996) 179:119-122.
37. EMBERTON M, NEAL DE, BLACK N et al.: The effect of prostatectomy on symptom severity and quality of life. Br. J. Urol. (1996) 77:233-247.
38. SCARPA RM: Lower urinary tract symptoms: what are the implications for the patients? Eur. Urol. (2001) 40(Suppl. 4):12-20.
39. 1-adrenoceptor antagonists on male sexual function. Drugs (2006) 66:287-301.
40. CHANG DF, CAMPBELL JR: Intraoperative floppy iris syndrome associated with tamsulosin. J. Cataract Refract. Surg. (2005) 31:664-673.
41. 1-adrenoceptor antagonists on pupil diameter and intraurethral pressure in rabbits. Jpn Pharmacol. Ther. (2006) 34:653-661.